These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 32321997)

  • 21. Diagnostic testing for uniparental disomy: a points to consider statement from the American College of Medical Genetics and Genomics (ACMG).
    Del Gaudio D; Shinawi M; Astbury C; Tayeh MK; Deak KL; Raca G;
    Genet Med; 2020 Jul; 22(7):1133-1141. PubMed ID: 32296163
    [No Abstract]   [Full Text] [Related]  

  • 22. Points to consider: is there evidence to support BRCA1/2 and other inherited breast cancer genetic testing for all breast cancer patients? A statement of the American College of Medical Genetics and Genomics (ACMG).
    Pal T; Agnese D; Daly M; La Spada A; Litton J; Wick M; Klugman S; Esplin ED; Jarvik GP;
    Genet Med; 2020 Apr; 22(4):681-685. PubMed ID: 31831881
    [No Abstract]   [Full Text] [Related]  

  • 23. Points to consider in the reevaluation and reanalysis of genomic test results: a statement of the American College of Medical Genetics and Genomics (ACMG).
    Deignan JL; Chung WK; Kearney HM; Monaghan KG; Rehder CW; Chao EC;
    Genet Med; 2019 Jun; 21(6):1267-1270. PubMed ID: 31015575
    [No Abstract]   [Full Text] [Related]  

  • 24. Considerations for policymakers for improving health care through telegenetics: A points to consider statement of the American College of Medical Genetics and Genomics (ACMG).
    Williams HE; Aiyar L; Dinulos MB; Flannery D; McClure ML; Lloyd-Puryear MA; Sanghavi K; Trotter TL; Viskochil D;
    Genet Med; 2022 Nov; 24(11):2211-2219. PubMed ID: 36040445
    [No Abstract]   [Full Text] [Related]  

  • 25. Stewardship of patient genomic data: A policy statement of the American College of Medical Genetics and Genomics (ACMG).
    Best RG; Khushf G; Rabin-Havt SS; Clayton EW; Grebe TA; Hagenkord J; Topper S; Fivecoat J; Chen M; Grody WW;
    Genet Med; 2022 Mar; 24(3):509-511. PubMed ID: 35253644
    [No Abstract]   [Full Text] [Related]  

  • 26. The clinical application of polygenic risk scores: A points to consider statement of the American College of Medical Genetics and Genomics (ACMG).
    Abu-El-Haija A; Reddi HV; Wand H; Rose NC; Mori M; Qian E; Murray MF;
    Genet Med; 2023 May; 25(5):100803. PubMed ID: 36920474
    [No Abstract]   [Full Text] [Related]  

  • 27. Contributions from medical geneticists in clinical trials of genetic therapies: A points to consider statement of the American College of Medical Genetics and Genomics (ACMG).
    Peña LDM; Burrage LC; Enns GM; Esplin ED; Harding C; Mendell JR; Niu ZN; Scharfe C; Yu T; Koeberl DD;
    Genet Med; 2023 Jun; 25(6):100831. PubMed ID: 37031408
    [No Abstract]   [Full Text] [Related]  

  • 28. Response to "The use of ACMG secondary findings recommendations for general population screening: a policy statement of the American College of Medical Genetics and Genomics (ACMG)".
    Nussbaum RL; Haverfield E; Esplin ED; Aradhya S
    Genet Med; 2019 Dec; 21(12):2836-2837. PubMed ID: 31239557
    [No Abstract]   [Full Text] [Related]  

  • 29. The interface of genomic information with the electronic health record: a points to consider statement of the American College of Medical Genetics and Genomics (ACMG).
    Grebe TA; Khushf G; Chen M; Bailey D; Brenman LM; Williams MS; Seaver LH;
    Genet Med; 2020 Sep; 22(9):1431-1436. PubMed ID: 32475985
    [No Abstract]   [Full Text] [Related]  

  • 30. Laboratory perspectives in the development of polygenic risk scores for disease: A points to consider statement of the American College of Medical Genetics and Genomics (ACMG).
    Reddi HV; Wand H; Funke B; Zimmermann MT; Lebo MS; Qian E; Shirts BH; Zou YS; Zhang BM; Rose NC; Abu-El-Haija A;
    Genet Med; 2023 May; 25(5):100804. PubMed ID: 36971772
    [No Abstract]   [Full Text] [Related]  

  • 31. Clinical utility of polygenic risk scores for embryo selection: A points to consider statement of the American College of Medical Genetics and Genomics (ACMG).
    Grebe TA; Khushf G; Greally JM; Turley P; Foyouzi N; Rabin-Havt S; Berkman BE; Pope K; Vatta M; Kaur S;
    Genet Med; 2024 Apr; 26(4):101052. PubMed ID: 38393332
    [No Abstract]   [Full Text] [Related]  

  • 32. Pediatric clinical exome/genome sequencing and the engagement process: encouraging active conversation with the older child and adolescent: points to consider-a statement of the American College of Medical Genetics and Genomics (ACMG).
    Bush LW; Bartoshesky LE; David KL; Wilfond B; Williams JL; Holm IA;
    Genet Med; 2018 Jul; 20(7):692-694. PubMed ID: 29565417
    [No Abstract]   [Full Text] [Related]  

  • 33. Toward automation of germline variant curation in clinical cancer genetics.
    Ravichandran V; Shameer Z; Kemel Y; Walsh M; Cadoo K; Lipkin S; Mandelker D; Zhang L; Stadler Z; Robson M; Offit K; Vijai J
    Genet Med; 2019 Sep; 21(9):2116-2125. PubMed ID: 30787465
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Points to consider for providing expert witness testimony for the specialty of medical genetics: A statement of the American College of Medical Genetics and Genomics (ACMG).
    Seaver LH; Chan P; Fleisher LD; Huang SJ; Klugman SD; Matalon DR;
    Genet Med; 2024 Oct; 26(10):101229. PubMed ID: 39240268
    [No Abstract]   [Full Text] [Related]  

  • 35. Correspondence on "ACMG SF v3.0 list for reporting of secondary findings in clinical exome and genome sequencing: a policy statement of the American College of Medical Genetics and Genomics (ACMG)" by Miller et al.
    McGurk KA; Zheng SL; Henry A; Josephs K; Edwards M; de Marvao A; Whiffin N; Roberts A; Lumbers TR; O'Regan DP; Ware JS
    Genet Med; 2022 Mar; 24(3):744-746. PubMed ID: 34906520
    [No Abstract]   [Full Text] [Related]  

  • 36. Technical laboratory standards for interpretation and reporting of acquired copy-number abnormalities and copy-neutral loss of heterozygosity in neoplastic disorders: a joint consensus recommendation from the American College of Medical Genetics and Genomics (ACMG) and the Cancer Genomics Consortium (CGC).
    Mikhail FM; Biegel JA; Cooley LD; Dubuc AM; Hirsch B; Horner VL; Newman S; Shao L; Wolff DJ; Raca G
    Genet Med; 2019 Sep; 21(9):1903-1916. PubMed ID: 31138931
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Correspondence on "Clinical utility of polygenic risk scores for embryo selection: A points to consider statement of the American College of Medical Genetics and Genomics (ACMG)" by Grebe et al.
    Widen E; Lello L; Eccles J; Marin D; Treff NR
    Genet Med; 2024 Aug; 26(8):101155. PubMed ID: 38856723
    [No Abstract]   [Full Text] [Related]  

  • 38. Tumor genome analysis includes germline genome: are we ready for surprises?
    Catenacci DV; Amico AL; Nielsen SM; Geynisman DM; Rambo B; Carey GB; Gulden C; Fackenthal J; Marsh RD; Kindler HL; Olopade OI
    Int J Cancer; 2015 Apr; 136(7):1559-67. PubMed ID: 25123297
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The use of fetal exome sequencing in prenatal diagnosis: a points to consider document of the American College of Medical Genetics and Genomics (ACMG).
    Monaghan KG; Leach NT; Pekarek D; Prasad P; Rose NC;
    Genet Med; 2020 Apr; 22(4):675-680. PubMed ID: 31911674
    [No Abstract]   [Full Text] [Related]  

  • 40. Application of ACMG criteria to classify variants in the human gene mutation database.
    Qu HQ; Wang X; Tian L; Hakonarson H
    J Hum Genet; 2019 Nov; 64(11):1091-1095. PubMed ID: 31451714
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.